bioxcell ip0070 Search Results


buffer  (Bio X Cell)
96
Bio X Cell buffer
Buffer, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bioxcell+ip0070/pm41850678-222-40-41?v=Bio+X+Cell
Average 96 stars, based on 1 article reviews
buffer - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
rat igg2b isotype control  (Bio X Cell)
97
Bio X Cell rat igg2b isotype control
A. Tumour volume in Alk-F1178S;Th-MYCN mice harbouring tumours treated with combination elimusertib and lorlatinib concurrent with injections of either anti-mouse CD8α (n=10 (day 0), n=10 (day 7), n=9 (day 14)) or <t>IgG2b</t> isotype control (n=5 (day 0), n=5 (day 7), n=4 (day 14)). Comparison of tumour volume differences between anti-mouse CD8α and IgG2b isotype controls at day 7 ( P =0.0007) and day 14 ( P =0.0755) determined by two-tailed Mann-Whitney test. B. Alk-F1178S;Th-MYCN mice harbouring tumours treated with H-151 (n=5) in addition to the 14 day combination treatment regime (elimusertib+lorlatinib). Tumour volume data presented as mean +/- SD. C. Kaplan-Meier survival curve (post-treatment) of Alk-F1178S;Th-MYCN mice harbouring tumours treated with H-151 (n=5) in addition to the 14 day combination treatment regime (elimusertib+lorlatinib). Gray dashed line shows survival curve for elimusertib and lorlatinib alone for comparison. D. Representative H&E/Mag stained treated Alk-F1178S;Th-MYCN tumour, showing distinct histological features within the same tumour, inserts are magnifications of dashed squares. E-F. Volcano plots showing GSEA results using cell type signature genes from PanglaoDB (E) and MSigDB (F) . Enrichment was performed using DGE between NB tumours from Alk-F1178S;Th-MYCN mice in untreated control conditions (n=6) and after 3 days of elimusertib treatment (n=3). Neuronal and Schwann cell-related gene sets are indicated. Bottom plots showing running score plots for the most enriched neuronal and Schwann cell-related gene sets. G. Sections from control and elimusertib treated tumours were stained for Mag, Sox10 and Mpz by immunohistochemistry. Treated tumours exhibited Mag and Mpz positivity in areas with enlarged cells resembling neuronal or Schwann cells. Control tumours were negative. Sox10 positive nuclei were present in both control and treated tumours. H. Representative differentiation morphology images of SK-N-BE(2) cells upon DMSO, retinoic acid (RA)(10 μM) or/and elimusertib (10 nM) treatment for 24h. I. Bar graphs indicate percentage of differentiated cells, neurite length (mm/mm 2 ), and neurite branch points (mm 2 ) following RA or/and elimusertib treatment. J. Immunoblot for neuronal differentiation markers (RET, DLG2, MAP2, NSE) in SK-N-BE(2) cells treated with retinoic acid (RA) or/and elimusertib for 24 h.
Rat Igg2b Isotype Control, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bioxcell+ip0070/bio_rxiv__2023__08__30__555570-374-11-29?v=Bio+X+Cell
Average 97 stars, based on 1 article reviews
rat igg2b isotype control - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier

Image Search Results


A. Tumour volume in Alk-F1178S;Th-MYCN mice harbouring tumours treated with combination elimusertib and lorlatinib concurrent with injections of either anti-mouse CD8α (n=10 (day 0), n=10 (day 7), n=9 (day 14)) or IgG2b isotype control (n=5 (day 0), n=5 (day 7), n=4 (day 14)). Comparison of tumour volume differences between anti-mouse CD8α and IgG2b isotype controls at day 7 ( P =0.0007) and day 14 ( P =0.0755) determined by two-tailed Mann-Whitney test. B. Alk-F1178S;Th-MYCN mice harbouring tumours treated with H-151 (n=5) in addition to the 14 day combination treatment regime (elimusertib+lorlatinib). Tumour volume data presented as mean +/- SD. C. Kaplan-Meier survival curve (post-treatment) of Alk-F1178S;Th-MYCN mice harbouring tumours treated with H-151 (n=5) in addition to the 14 day combination treatment regime (elimusertib+lorlatinib). Gray dashed line shows survival curve for elimusertib and lorlatinib alone for comparison. D. Representative H&E/Mag stained treated Alk-F1178S;Th-MYCN tumour, showing distinct histological features within the same tumour, inserts are magnifications of dashed squares. E-F. Volcano plots showing GSEA results using cell type signature genes from PanglaoDB (E) and MSigDB (F) . Enrichment was performed using DGE between NB tumours from Alk-F1178S;Th-MYCN mice in untreated control conditions (n=6) and after 3 days of elimusertib treatment (n=3). Neuronal and Schwann cell-related gene sets are indicated. Bottom plots showing running score plots for the most enriched neuronal and Schwann cell-related gene sets. G. Sections from control and elimusertib treated tumours were stained for Mag, Sox10 and Mpz by immunohistochemistry. Treated tumours exhibited Mag and Mpz positivity in areas with enlarged cells resembling neuronal or Schwann cells. Control tumours were negative. Sox10 positive nuclei were present in both control and treated tumours. H. Representative differentiation morphology images of SK-N-BE(2) cells upon DMSO, retinoic acid (RA)(10 μM) or/and elimusertib (10 nM) treatment for 24h. I. Bar graphs indicate percentage of differentiated cells, neurite length (mm/mm 2 ), and neurite branch points (mm 2 ) following RA or/and elimusertib treatment. J. Immunoblot for neuronal differentiation markers (RET, DLG2, MAP2, NSE) in SK-N-BE(2) cells treated with retinoic acid (RA) or/and elimusertib for 24 h.

Journal: bioRxiv

Article Title: ALK signalling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition

doi: 10.1101/2023.08.30.555570

Figure Lengend Snippet: A. Tumour volume in Alk-F1178S;Th-MYCN mice harbouring tumours treated with combination elimusertib and lorlatinib concurrent with injections of either anti-mouse CD8α (n=10 (day 0), n=10 (day 7), n=9 (day 14)) or IgG2b isotype control (n=5 (day 0), n=5 (day 7), n=4 (day 14)). Comparison of tumour volume differences between anti-mouse CD8α and IgG2b isotype controls at day 7 ( P =0.0007) and day 14 ( P =0.0755) determined by two-tailed Mann-Whitney test. B. Alk-F1178S;Th-MYCN mice harbouring tumours treated with H-151 (n=5) in addition to the 14 day combination treatment regime (elimusertib+lorlatinib). Tumour volume data presented as mean +/- SD. C. Kaplan-Meier survival curve (post-treatment) of Alk-F1178S;Th-MYCN mice harbouring tumours treated with H-151 (n=5) in addition to the 14 day combination treatment regime (elimusertib+lorlatinib). Gray dashed line shows survival curve for elimusertib and lorlatinib alone for comparison. D. Representative H&E/Mag stained treated Alk-F1178S;Th-MYCN tumour, showing distinct histological features within the same tumour, inserts are magnifications of dashed squares. E-F. Volcano plots showing GSEA results using cell type signature genes from PanglaoDB (E) and MSigDB (F) . Enrichment was performed using DGE between NB tumours from Alk-F1178S;Th-MYCN mice in untreated control conditions (n=6) and after 3 days of elimusertib treatment (n=3). Neuronal and Schwann cell-related gene sets are indicated. Bottom plots showing running score plots for the most enriched neuronal and Schwann cell-related gene sets. G. Sections from control and elimusertib treated tumours were stained for Mag, Sox10 and Mpz by immunohistochemistry. Treated tumours exhibited Mag and Mpz positivity in areas with enlarged cells resembling neuronal or Schwann cells. Control tumours were negative. Sox10 positive nuclei were present in both control and treated tumours. H. Representative differentiation morphology images of SK-N-BE(2) cells upon DMSO, retinoic acid (RA)(10 μM) or/and elimusertib (10 nM) treatment for 24h. I. Bar graphs indicate percentage of differentiated cells, neurite length (mm/mm 2 ), and neurite branch points (mm 2 ) following RA or/and elimusertib treatment. J. Immunoblot for neuronal differentiation markers (RET, DLG2, MAP2, NSE) in SK-N-BE(2) cells treated with retinoic acid (RA) or/and elimusertib for 24 h.

Article Snippet: Treatment was started on day 0 with either anti-mouse CD8α or rat IgG2b isotype control (intraperitoneal injection, 100 μl, 2 mg/kg, diluted in InVivo Pure pH 7.0 Dilution buffer (BioXcell, Catalog #IP0070)).

Techniques: Control, Comparison, Two Tailed Test, MANN-WHITNEY, Staining, Immunohistochemistry, Western Blot